Bausch + Lomb reports its September-quarter results before markets open on October 28, 2026. Analysts expect earnings of C$0.22 per share, up from C$0.18 a year ago, and revenue of about US$1.36 billion, a 6.4% increase. The company has beaten estimates in two of its last four comparable quarters and matched them in its most recent report. Follow BLCO.TO results and company fundamentals on the Bausch + Lomb stock page.
Investor takeaway: Analysts expect year-over-year growth, but that doesn’t guarantee an earnings surprise. The results will show whether sales growth is translating into stronger earnings as the company pursues its Vision 27 efficiency program. Leadership changes and developments in manufacturing and its product pipeline provide context, but the reported results matter most.
Recent earnings trend
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.74B
52W high
$25.70
52W low
$20.25
1W change
+3.83%
Beta
0.56
Analyst Price Targets
Based on analyst covering BLCO · as of Oct 26, 2026
Wall Street analysts forecast BLCO stock price to rise 2.5% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.01
+2.5% Upside
Previously C$25.07 on Oct 23, 2026
Current Price
C$24.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
36.1%
Annualized
90-Day Vol
31.0%
Annualized
Trend (90d)
+18.8%
Annualized drift
90d Mean
C$26.16
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$25.01 | C$22.09 – C$28.33 |
| 60 trading days | C$25.58 | C$21.45 – C$30.50 |
| 90 trading days | C$26.16 | C$21.09 – C$32.45 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Analyst coverage: 11 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-10-28 | — | 0.2200 | — |
| 2026-06-30 | 2026-07-29 | 0.1600 | 0.1600 | +0.0% |
| 2026-03-31 | 2026-04-29 | 0.0800 | 0.0600 | +33.3% |
| 2025-12-31 | 2026-02-18 | 0.3200 | 0.3600 | -11.1% |
| 2025-09-30 | 2025-10-29 | 0.1800 | 0.1600 | +12.5% |
| 2025-06-30 | 2025-07-30 | 0.0700 | 0.0900 | -22.2% |
Advertisement
C$0.22 EPS consensus
Eleven analysts expect earnings of C$0.22 per share, with estimates ranging from C$0.19 to C$0.24. A year ago, EPS was C$0.18. The same analysts expect revenue of US$1.36 billion. The EPS consensus has stayed at C$0.22 over the past 30 days, even as two analysts raised estimates and six lowered them.
Bull case
Analysts expect EPS to rise 21.5% from a year ago and revenue to grow 6.4%. Bausch + Lomb beat estimates in two of its last four comparable quarters, including an EPS result 33.3% above expectations in March 2026. If sales growth and cost controls support earnings, the report could strengthen the case for improving profitability.
Bear case
The company’s recent results have been mixed: it missed estimates in December 2025, met them in June 2026, and beat them in March and September 2025. EPS estimates haven’t changed over the past 30 days, and more analysts lowered their forecasts than raised them. Bausch + Lomb also has negative trailing-twelve-month EPS and a negative profit margin, so forecast growth alone doesn’t show that profitability has recovered. Investors may also watch how leadership executes and how the company responds to the FDA warning letter about sterile manufacturing at its Tampa facility.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
